Algert Global’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.2M Buy
506,273
+51,810
+11% +$963K 0.13% 228
2026
Q1
$8.24M Buy
454,463
+183,160
+68% +$3.16M 0.12% 270
2025
Q4
$5.31M Sell
271,303
-243,829
-47% -$4.62M 0.08% 413
2025
Q3
$6.52M Sell
515,132
-43,764
-8% -$499K 0.11% 330
2025
Q2
$5.32M Buy
558,896
+82,889
+17% +$913K 0.11% 304
2025
Q1
$4.98M Buy
476,007
+395,084
+488% +$5.65M 0.12% 277
2024
Q4
$1.91M Sell
80,923
-14,037
-15% -$415K 0.04% 622
2024
Q3
$3.41M Sell
94,960
-2,410
-2% -$95.9K 0.09% 379
2024
Q2
$3.44M Buy
97,370
+69,947
+255% +$2.03M 0.11% 291
2024
Q1
$779K Sell
27,423
-133,581
-83% -$3.02M 0.03% 682
2023
Q4
$2.14M Buy
161,004
+2,291
+1% +$22.4K 0.09% 395
2023
Q3
$1.42M Sell
158,713
-80,359
-34% -$866K 0.07% 482
2023
Q2
$2.69M Buy
239,072
+47,200
+25% +$557K 0.12% 279
2023
Q1
$2.21M Buy
191,872
+38,227
+25% +$496K 0.1% 308
2022
Q4
$1.78M Sell
153,645
-1,450
-0.9% -$16.8K 0.1% 332
2022
Q3
$1.97M Buy
155,095
+136,540
+736% +$1.57M 0.12% 274
2022
Q2
$127K Buy
+18,555
New +$128K 0.01% 1084

Other funds holding DYN

Algert Global's DYN Position: Q2 2026 in Review

Algert Global increased its Dyne Therapeutics (DYN) stake by 11% in Q2 2026, buying an estimated $963K and bringing the position to 506,273 shares worth $11.2M. The position accounts for 0.13% of the portfolio, ranked #228.

Algert Global first reported a position in DYN in Q2 2022 and has held it in 17 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Algert Global held 506,273 shares of Dyne Therapeutics worth $11.2M as of Q2 2026.
  • Algert Global bought 51,810 Dyne Therapeutics shares in Q2 2026, an estimated $963K.
  • Dyne Therapeutics made up 0.13% of Algert Global's portfolio in Q2 2026, its #228 holding.
  • Algert Global first reported a position in Dyne Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.